NCT02023151View on ClinicalTrials.gov

Predicting the Clinical Response to Omalizumab With Anti-Immunoglobulin E (IgE) Ab Response or Syk Expression in Basophils

PHASE4CompletedINTERVENTIONAL

Enrollment

17

Participants

Timeline

Start Date

February 28, 2013

Primary Completion Date

June 30, 2016

Study Completion Date

August 31, 2016

Conditions

Allergic Asthma

Interventions

DRUG

Omalizumab

Trial Locations (1)

21212

Johns Hopkins Asthma & Allergy Center, Baltimore

Sponsors

Collaborators (1)

Novartis Pharmaceuticals

All Listed Sponsors

collaborator

Novartis Pharmaceuticals

INDUSTRY

lead

Johns Hopkins University

OTHER